Previous 10 | Next 10 |
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn. , Aug. 1, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release ...
NEW PUBLICATION SUPPORTS THE USE OF CALDOLOR® IN NEWBORN PEDIATRIC PATIENTS PR Newswire NASHVILLE, Tenn. , June 26, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) , a specialty pharmaceutical company, today announced the pub...
2023-05-23 10:53:28 ET The US FDA has cleared Cumberland Pharmaceuticals' ( NASDAQ: CPIX ) Investigational New Drug application for ifetroban for idiopathic pulmonary fibrosis. The IND is for a phase 2 study of the selective thromboxane receptor antagonist candidate. ...
CUMBERLAND PHARMACEUTICALS ANNOUNCES FDA CLEARANCE OF IND FOR NEW TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS PR Newswire Cumberland initiating Phase II FIGHTING FIBROSIS ™ clinical trial, Newest program in Cumberland's ifetroban pipeline NA...
CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS PR Newswire Caldolor ® is the only injectable non-opioid approved for treating pain in infants NASHV...
2023-05-09 16:54:43 ET Cumberland Pharmaceuticals press release ( NASDAQ: CPIX ): Q1 Non-GAAP EPS of $0.11. Revenue of $9.2M (-17.9% Y/Y). For further details see: Cumberland Pharmaceuticals Non-GAAP EPS of $0.11, revenue of $9.2M
Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update PR Newswire NASHVILLE, Tenn. , May 9, 2023 /PRNewswire/ -- Cumberland P...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn. , May 2, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release th...
2023-03-07 22:47:02 ET Cumberland Pharmaceuticals Inc. (CPIX) Q4 2022 Earnings Conference Call March 07, 2023, 04:30 PM ET Company Participants Molly Aggas - Account Supervisor, Dalton Agency A.J. Kazimi - CEO Todd Anthony - VP, Organizational Development Joh...
2023-03-07 16:25:41 ET Cumberland Pharmaceuticals press release ( NASDAQ: CPIX ): FY GAAP EPS of -$0.17. Revenue of $9.12M (+9.9% Y/Y). For further details see: Cumberland Pharmaceuticals GAAP EPS of -$0.17, revenue of $9.12M
News, Short Squeeze, Breakout and More Instantly...
Cumberland Pharmaceuticals Inc. Company Name:
CPIX Stock Symbol:
NASDAQ Market:
Cumberland Pharmaceuticals Inc. Website:
Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update PR Newswire NASHVILLE, TENN . , May 7, 2024 /PRNewswire/ -- Cumberland Ph...
Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...
CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS PR Newswire NASHVILLE, Tenn. , April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release ...